Börsenbriefempfehlung mit Kurspotential 100 % ...

Zitat:"“We are pleased to report strong revenue growth in the 3rd quarter despite the challenges presented by COVID-19. Epidiolex meets a serious unmet need within the field of epilepsy and we expect the product to demonstrate continued strong growth in the months and years ahead. The recent expanded indication for the treatment of seizures associated with TSC has been very well received by patients, clinicians and payers,” stated Justin Gover, GW’s Chief Executive Officer. “We have also now commenced the pivotal Phase 3 program for nabiximols in the treatment of multiple sclerosis spasticity, which provides multiple opportunities for an NDA submission, including as early as next year. Beyond nabiximols, we are advancing several clinical-stage pipeline candidates, including the recent start of a Phase 2 trial in schizophrenia.”.......

FINANCIAL RESULTS...............    Total revenue for the quarter ended September 30, 2020 was $137.1 million compared to $91.0 million for the quarter ended September 30, 2019
   Total revenue for the first nine months of 2020 of $378.6 million compared to $202.3 million in the prior year period
   Net loss for the quarter ended September 30, 2020 was $12.2 million compared to net loss of $13.8 million for the quarter ended September 30, 2019
   Cash and cash equivalents at September 30, 2020 were $480.3 million...................OPERATIONAL HIGHLIGHTS.......... ENDE Zitat
Source/Quelle:https://www.stockwatch.com/News/...01103&symbol=GWPH&region=U

   Epidiolex (cannabidiol) progress:
       Total Q3 net product sales of Epidiolex of $132.6 million
       U.S. commercial update
           U.S. Epidiolex Q3 net product sales of $121.6 million
           

Gaps im Auge behalten,...

kurz hoch bis 116er range.,... dann kurzer ruecksetzter und dann ueber das gap (IMO - siehe Profilangaben)..... kann aber auch einen Run geben,... denke aber eher nicht (8-ung Kontraindikator;- )

https://www.stockwatch.com/Chart/...me=1&symbol=GWPH&region=U  

https://www.stockwatch.com/Chart/...me=1&symbol=GWPH&region=U  

bis 91$ IMO möglich,.... irgendwann
http://www.stockta.com/cgi-bin/...mb=GWPH&cobrand=&mode=stock  

Zahlen für Q3/20

• Epidiolex-Umsätze 137 Mio. $ (+51% zum VJQ)
  
• Erwartungen ~127 Mio. $
  

https://ir.gwpharm.com/news-releases/...-third-quarter-2020-financial

https://www.fool.com/investing/2020/11/03/...-away-expectations-with/

 

EPIDIOLEX® (cannabidiol) werden Peak Sales von ~1 Mrd. $ prognostizert.
https://www.fiercebiotech.com/special-report/16-epidiolex  

 

 

 

 

 

Zitat:"...GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW’s Chief Executive Officer, will present a business update and 2021 outlook at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 10:00 am ET (7:00 am PT). In addition, a Q&A breakout session will immediately follow the presentation at 10:20 am ET (7:20 am PT)...:" ENDE Zitat
Quelle:https://www.stockwatch.com/News/...10105&symbol=GWPH&region=U

unklar wie GW diese Woche gen Nord zieht..... ob es am kommenden Dienstag handfeste News gibt..? und jetzt schon ein paar wenige sich eindecken..... tz tz tz  

 

bei um die $129sollte plus/minus geschlossen sein...
altes Gap (ebenfalls in #62 bereits zu sehen) bei $91-96  (als Worst-Case )
neues Gap bei $116-118 (Korrekturziel nach Übertreibung)
*Open Gaps
 Direction      Date     range§
up Jan-06-2021 116.37 to 118.99
up Nov-03-2020 91.02 to 96.5
*Year Hi-Lo
143.9999 -  67.98
Quelle:http://www.stockta.com/cgi-bin/...mb=GWPH&cobrand=&mode=stock

Quelle-Chart:https://www.stockwatch.com/Chart/...me=1&symbol=GWPH&region=U  

 

 

 

Zitat:"Our system’s recommendation today is to STAY LONG. The previous BUY signal was issued on 01/05/2021, 3 days ago, when the stock price was 116.2500.......Candlesticks warned us today to be on alert with a new bearish pattern."

Quelle/zeitversetzt ! : https://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=GWPH  

 

Zitat:" Total preliminary net product sales of approximately $148 million for the fourth quarter and approximately $526 million for the full year -
- Total Epidiolex® preliminary net product sales of approximately $144 million for the fourth quarter and approximately $510 million for the full year –
- Pivotal US clinical program for nabiximols in MS spasticity underway. Initial data expected in 2021 -,,, Ende Zitat

Quelle:https://www.stockwatch.com/News/...10111&symbol=GWPH&region=U

https://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=GWPH   !!!  

Fehlsignal vs. W-Formation

https://www.barchart.com/stocks/quotes/GWPH/interactive-chart ( PriceTarget ? 2-Y.Chart)

*subjektive Einschätzung - keinerlei Aufforderung zum Handeln - eigene Recherche betreiben -
keine Kaufempfehlung ! siehe Profilbild*



 

MK 4,8 Mrd. $  

Zitat:"...Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and GW Pharmaceuticals plc (Nasdaq: GWPH) today announced the companies have entered into a definitive agreement for Jazz to acquire GW for $220.00 per American Depositary Share (ADS), in the form of $200.00 in cash and $20.00 in Jazz ordinary shares.."
Quelle:https://www.stockwatch.com/News/...10203&symbol=GWPH&region=U  

Jazz Pharmaceuticals übernimmt GWPH in einem 7,2 Mrd. $ Deal

• 200$ in Cash
  
• 20$ in Jazz Aktien
  
• 50% Premium
  

https://www.benzinga.com/general/biotech/21/02/...-gw-pharma-for-7-2b

 

Wie gestern Abend bekannt wurde, will das irische Pharmaunternehmen Jazz Pharmaceuticals für 7,2 Milliarden Dollar (rund sechs Milliarden Euro) die britische Firma GW Pharmaceuticals übernehmen. GW Pharmaceuticals ist bekannt geworden weil Sie verschiedene Cannabismedikament herstellen.

https://hanfseite.de/gw-pharma/